A Multicenter, Single Arm Study Evaluating The Extension From Weekly To Once Every Other Week Darbepoetin Alfa Administration In Subjects With Chronic Kidney Disease Receiving Dialysis

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-000074-79

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the proportion of subjects successfully achieving a mean Hemoglobin (Hb) ≥ 11 g/dL during the evaluation period following extension from QW to Q2W darbepoetin alfa administration.


Critère d'inclusion

  • Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis